Advanced Filters
noise

Isleworth, United Kingdom Clinical Trials

A listing of Isleworth, United Kingdom clinical trials actively recruiting patients volunteers.

Found 672 clinical trials

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find out if OVM-200 is safe to continue studying it in patients with cancer. The Study consists of …

18 - 75 years of age All Phase 1
F Fayaz Master

Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer

The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1/Modi-1v vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab (where these are standard of care in a non-neoadjuvant setting), in patients with …

18 years of age All Phase 1/2

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

This is a Phase Ib study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL)

- 18 years of age All Phase 1
T Trial Manager

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

The aim of this study is to assess the rates of circulating tumour DNA (ctDNA) in patients treated with surgery for stage 1 breast cancer that is HER2 positive or triple negative. The study will involve collecting blood samples from patients before and after surgery, if patients are enrolled after …

18 years of age All Phase N/A
S Shivani Misra, MBBS, MRCP

RT-CGM in Young Adults at Risk of DKA

Pilot study to evaluate the effect of real time continuous glucose monitoring (RT-CGM) on young-adults with insulin-treated diabetes, who are defined as high risk due to suboptimal HbA1c (blood glucose control) or a history of hospital admissions for high blood glucoses. Hypothesis: RT-CGM provided to young adults with suboptimal blood …

18 - 25 years of age All Phase N/A

Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

This study is being carried out to see if the drug atezolizumab can reduce the size of tumours in patients with types of urothelial cancer before surgery. Atezolizumab is designed to stop a protein called PD-L1 (programmed death-ligand 1) being expressed on the cancer, allowing the immune system to recognise …

18 - 99 years of age All Phase 2
V Vishal Patel

A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis

A feasibility trial called PROFIT has previously shown that FMT administered endoscopically into the jejunum in patients with cirrhosis is safe and feasible and have identified some potential mechanisms of action that warrant further interrogation. The aim of the PROMISE Trial is to evaluate the efficacy and mechanisms of action …

18 years of age All Phase 3

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

Phase II, multicentre, randomised, open-label study to assess the benefit of early intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell lymphoma (MCL)

18 years of age All Phase 2
A Aida Suarez-Gonzalez, Dr

BELIDE: Better Living With Non-memory-led Dementia

Around 48 million people worldwide 1 live with dementia, of whom 3.9 million start with symptoms before the age of 65 (young-onset dementia). Most of the people presenting with young-onset dementia and some people with later onset dementia develop non-memory led dementias such as the atypical forms of Alzheimer ́s …

18 years of age All Phase N/A

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02.

25 - 70 years of age All Phase 1

Simplify language using AI